Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease

NCT05148884 is registered in ClinicalTrials.gov with Neurolixis SAS as lead sponsor.

NCT NCT05148884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05148884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease
Lead sponsor
Neurolixis SAS
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2021
Completion date
January 18, 2023
Enrollment
27 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

medication-induced dyskinesia